Creators

FierceBiotech

The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.

@fiercebiotech 102.9K X followersFirst product launched 10y ago

Total monthly visits
879.4K
Down0.6%MoMOct 2026
Public revenue
Undisclosed
No public revenue across products
Products
1
Since Mar 2016
Latest launch
10y ago
Fierce Biotech879.4K visits/mo
100% full-depth creator dossier open: complete product portfolio, 12-month combined traffic & MRR curves, shipping cadence, and timeline events.

Traffic

Portfolio · Last 12 months
Monthly visits

Products

Products and research metrics
ProductVisits · OctActions
Fierce BiotechFierce Biotech News & Reports879.4K

Timeline

Launches, marketing, revenue milestones, and pricing/plan/positioning changes across products
  1. Nov 18 · 5d ago

    • Fierce Biotech reports Pfizer's deal for Starna's CAR-T programsReferrals & Backlinks

      Fierce Biotech reports that Pfizer agreed to a deal worth up to $2.6 billion for three preclinical autoimmune programs from Starna Therapeutics, including $330 million upfront.

  2. Nov 17 · 6d ago

    • Fierce Biotech reports Marrow Therapeutics' launch and $173 million fundingReferrals & Backlinks

      Fierce Biotech reports that Marrow Therapeutics has launched with $173 million in funding. The funding will advance a preclinical therapy targeting sickle cell disease and beta thalassemia.

    • Fierce Biotech reports Isomorphic Labs' $5 billion Series CReferrals & Backlinks

      Fierce Biotech reports that Isomorphic Labs raised $5 billion in a Series C, six months after securing $2.1 billion for its AI drug development platform.

    • Fierce Biotech reports Kyntra Bio scrapping its phase 2 cancer programReferrals & Backlinks

      Fierce Biotech reports that Kyntra Bio, formerly FibroGen, scrapped its phase 2 prostate cancer ADC program after it failed to meet an efficacy threshold.

    • Fierce Biotech covers European biotech funding discussion at London Life Sciences WeekReferrals & Backlinks

      Fierce Biotech's coverage describes investors weighing Europe's biotech funding challenges and opportunities at its London Life Sciences Week event. The article asks whether 2027 could be Europe's year to shine.

  3. Nov 13 · 10d ago

    • Fierce Biotech reports positive phase 2 results for Regeneron's baloncibartReferrals & Backlinks

      Fierce Biotech reports that baloncibart met the primary endpoint in a phase 2 trial for POTS. Regeneron plans to launch a potentially pivotal study in 2027.

    • Fierce Biotech reports Rezera delaying its IPOReferrals & Backlinks

      Fierce Biotech reports that Rezera delayed its public offering, citing market conditions. This is a later development of Fierce Biotech's earlier coverage of Rezera's IPO target.

    • Fierce Biotech reports Windward Bio's $225M IPO targetReferrals & Backlinks

      Fierce Biotech reports that Sanofi-backed Windward Bio has hit its $225M IPO target to advance its respiratory pipeline.

  4. Nov 5 · 18d ago

    • Fierce Biotech covers Rezera's $181 million IPO targetReferrals & Backlinks

      Fierce Biotech reports that Rezera, formerly NodThera, is targeting $181 million in IPO proceeds to fund a phase 3 trial for its lead NLRP3 inhibitor.

    • Fierce Biotech covers Evommune's $1.1B deal with Hinova PharmaReferrals & Backlinks

      Fierce Biotech reports that Evommune signed a deal worth up to $1.1 billion with Hinova Pharmaceuticals to develop VAV1-targeting molecular glue degraders.

Questions & evidence

What products has FierceBiotech built?
FierceBiotech tracks 1 standalone software products on EarlyLore (1 currently live), led by Fierce Biotech.
How much website traffic do FierceBiotech's products get?
Across tracked standalone domains with web traffic estimates, FierceBiotech's portfolio reaches 879.4K combined monthly visits in each site's latest observed month. Coverage excludes shared third-party hosts and store listings.

Related indie founder research guides